Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Supraorbital Vibration as an Adjuvant to Topical Anesthesia During Intravitreal Therapy.

Journal of vitreoretinal diseases·2026

Same author

Pediatric Radiation Retinopathy: Impact of Early Diagnosis and Targeted Treatment.

Journal of vitreoretinal diseases·2026

Same author

Brachytherapy for choroidal metastasis secondary to primary urethral adenocarcinoma of Müllerian origin: A case report.

American journal of ophthalmology case reports·2025

Same author

Passion: The Force Driving Medicine.

Journal of vitreoretinal diseases·2025

Same author

Combined Cataract and Vitrectomy Surgery in Pediatric Patients.

Medicina (Kaunas, Lithuania)·2025

Same author

Update on Retinoblastoma Therapies.

Medicina (Kaunas, Lithuania)·2025

Search research articles

Related Experiment Video

Updated: Aug 4, 2025

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Erdafitinib-Induced Secondary Maculopathy.

Brian Becker¹, Sophia El Hamichi¹, Aaron S Gold¹

¹Miami Ocular Oncology & Retina, Miami, FL, USA.

Journal of Vitreoretinal Diseases

|April 3, 2023

Summary

This summary is machine-generated.

Erdafitinib (Balversa) can cause secondary maculopathy, leading to vision loss in bladder cancer patients. Discontinuing the drug improved vision and ocular anatomy, highlighting FGFR inhibitor-related ocular toxicity.

Keywords:

FGFR MAPK RPE detachment central serous chorioretinopathy erdafitinib mitogen-activated protein kinase retinopathy targeted therapy

More Related Videos

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Related Experiment Videos

Last Updated: Aug 4, 2025

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Area of Science:

Ophthalmology
Oncology
Pharmacology

Background:

Fibroblast growth factor receptor (FGFR) signaling is crucial for retinal pigment epithelium maintenance.
Erdafitinib targets the FGFR pathway, inhibiting cell proliferation and survival pathways.

Observation:

A 58-year-old man developed blurry vision and subretinal fluid after starting erdafitinib for urothelial carcinoma with bone metastasis.
Ocular findings progressed with continued erdafitinib treatment, leading to vision deterioration.

Findings:

Erdafitinib use was associated with secondary maculopathy, characterized by multifocal pigment epithelial detachments and subretinal fluid.
Discontinuation of erdafitinib resulted in improvement of both visual acuity and ocular anatomical features.

Implications:

This case highlights the potential for erdafitinib-induced ocular toxicity, specifically maculopathy.
Awareness of FGFR inhibitor-related visual side effects is critical for managing patients with urothelial carcinoma.
Monitoring for and prompt management of visual changes are essential during erdafitinib therapy.